Finance

Beta
Lists
APGE:NASDAQ
Apogee Therapeutics Inc
$132.69
-0.14%
(-0.19) 1D
$132.69
0.00% (0.00)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for APGE...
Open
$132.90
High
$133.00
Low
$132.64
Mkt. cap
9.98B
Avg. vol.
3.42M
Volume
7.74M
52-wk high
$133.16
52-wk low
$34.34
EPS
-$4.33
Shares outstanding
61.70M
No. of employees
261
Open
$132.90
High
$133.00
Low
$132.64
Mkt. cap
9.98B
Avg. vol.
3.42M
Volume
7.74M
52-wk high
$133.16
52-wk low
$34.34
EPS
-$4.33
Shares outstanding
61.70M
No. of employees
261
News stories
From sources across the web
About Apogee Therapeutics Inc
CEO-
Employees261
Founded2022
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websiteapogeetherapeutics.com
Analyst Ratings
Based on 16 analysts giving stock ratings to APGE in the past 3 months
Hold
Buy
3
Hold
13
Sell
0
12 month forecast
Based on 16 Wall Street analysts offering 12 month price targets for APGE in the last 3 months.
Highest
Current $132.69
$140.00 (+5.51%)
Average
$128.81 (-2.92%)
Lowest
$81.00 (-38.96%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Alex Thompson CFA
Stifel Nicolaus
Hold
Downgraded
$135.00
+1.7%
06/24/2026
Joseph Catanzaro
Mizuho Securities
Hold
Downgraded
$135.00
+1.7%
06/24/2026
Tyler Van Buren
TD Cowen
Hold
Downgraded
$132.55
-0.1%
06/24/2026
Seamus Fernandez
Guggenheim
Hold
Downgraded
$135.00
+1.7%
06/23/2026
Geoff Meacham
Citi
Hold
Downgraded
$135.00
+1.7%
06/23/2026
Brian Abrahams
RBC Capital
Hold
Downgraded
$135.00
+1.7%
06/23/2026
Michael Yee
UBS
Hold
Downgraded
$135.11
+1.8%
06/23/2026
David Hoang
Deutsche Bank
Hold
Downgraded
$135.00
+1.7%
06/23/2026
Adam Vogel
Craig-Hallum
Hold
Downgraded
$135.11
+1.8%
06/22/2026
David Nierengarten
Wedbush
Hold
Downgraded
$135.00
+1.7%
06/23/2026
Edward Nash
Canaccord Genuity
Hold
Downgraded
$135.11
+1.8%
06/23/2026
Julian Harrison
BTIG
Buy
Reiterated
$137.00
+3.2%
06/19/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$131.00
-1.3%
06/11/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$89.00
-32.9%
06/10/2026
Danielle Brill
Truist Financial
Hold
Reiterated
$81.00
-39%
05/28/2026
Qize Ding
Rothschild & Co Redburn
Buy
Initiated
$140.00
+5.5%
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
55.70M
54.18M
58.44M
60.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.46M
17.10M
19.61M
21.95M
Operating expense
73.16M
71.28M
78.06M
82.77M
Total operating expenses
73.16M
71.28M
78.06M
82.77M
Operating income
-73.16M
-71.28M
-78.06M
-82.77M
Other non operating income
-
-
-
-
EBT including unusual items
-66.02M
-64.96M
-69.32M
-74.03M
EBT excluding unusual items
-66.02M
-64.96M
-69.32M
-74.03M
Income tax expense
72.00K
61.00K
62.00K
79.00K
Effective tax rate
-0.11%
-0.09%
-0.09%
-0.11%
Other operating expenses
-
-
-
-
Net income
-66.10M
-65.02M
-69.39M
-74.11M
Net profit margin
-
-
-
-
Earnings per share
-1.13
-1.11
-1.03
-1.06
Interest and investment income
7.14M
6.32M
8.73M
8.74M
Interest expense
-
-
-
-
Net interest expenses
7.14M
6.32M
8.73M
8.74M
Depreciation and amortization charges
-
-
-
-
EBITDA
-72.77M
-70.87M
-77.65M
-82.36M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer